Drug Trial Radar · NCT00721955
Staccato Loxapine in Agitated Patients With Bipolar Disorder
Last checked: Nov 20, 2026Latest source record: Jul 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
314
Actual
Start
Jul 2008
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Alexza Pharmaceuticals, Inc.Not stated
- Sponsor type
- Not stated
- First posted
- Jul 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in bipolar 1 disorder patients.
Conditions
- Bipolar I Disorder
Interventions
Inhaled PlaceboDrug
Inhaled loxapine Placebo, may repeat after 2 hours x 2
Inhaled loxapine 5 mgDrug
Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
Inhaled loxapine 10 mgDrug
Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With PlaceboTime frame: Baseline and 2 hours
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Synergy Escondido
Escondido, California
Collaborative NeuroScience Network, Inc.
Garden Grove, California
Atlanta Center for Medical Research
Atlanta, Georgia
FutureSearch Trials
Austin, Texas
Claghorn-Lesem Research Clinic
Houston, Texas
Northwest Clinical Research Center
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.